AIM ImmunoTech (NYSE:AIM) Trading Down 15.5% - Time to Sell?

AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report) shares fell 15.5% on Wednesday . The company traded as low as $8.20 and last traded at $8.58. 6,352 shares were traded during trading, a decline of 99% from the average session volume of 571,431 shares. The stock had previously closed at $10.15.

AIM ImmunoTech Stock Down 15.8%

The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75. The stock's 50-day moving average price is $0.30 and its two-hundred day moving average price is $0.21. The stock has a market capitalization of $618.08 million, a PE ratio of -18.19 and a beta of 0.76.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.